Moderna 2022 Priorities and Capital Allocation
Primary series and booster update in adolescent and
pediatric populations
•
Slide 22
SpikevaxⓇ/Moderna COVID-19 Vaccine in ages <18
In adolescents aged 12-17 years:
-
-
Primary series (2 dose, 100 µg) authorized/approved in more
than 40 countries
Submitted EUA for boosters globally
Submitted longer term safety follow ups to US FDA
In children aged 6-11 years:
-
Primary series (2 dose series, 50 µg) authorized/approved in
more than 35 countries
Evaluating a booster dose
In children aged 6 months to 5 years:
-
-
Announced in March that the primary series (2 dose series, 25
μg) met primary endpoint
EUA request submitted to US FDA: filed variations in the EU,
Canada and to additional global regulatory authorities
Evaluating a booster dose
whonjour.
Modems vous invite a fare la connassan
(vaccin contre la COVID-19)
since de fokevar
spikevax por modera
Moderna invite
mello
Hallo.
Moderna stelt vor Spieva(COVD-19-impo
Bevak (COVID-19
Hola!
Modeme le nts a conocer spevacuna contra is COVD-19)
pikevax by mod
spikevax von modoma
Sspikevax de modema
modernaView entire presentation